Delivery Order SPE2DB20D3303-SPE2DB25FA3MA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on September 2, 2025, with a ceiling value of $23,791.44 and firm fixed pricing. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $11,923.60 to AmerisourceBergen Drug Corp for the supply of INLYTA 1 mg tablets (180-count units). This contract utilizes a firm fixed-price structure with no set-aside designation, indicating competitive award selection. The delivery order is scheduled for completion by August 15, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. INLYTA is a targeted cancer therapy...
- The Defense Logistics Agency awarded a delivery order valued at $11,895.72 to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60 count) on August 12, 2025, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. INLYTA is a prescription pharmaceutical used in the treatment of certain cancers, reflecting...
- The Defense Logistics Agency awarded a $11,895.72 delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of INLYTA 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This firm fixed price delivery order, with an ultimate completion date of September 8, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $11,895.72 by the Defense Logistics Agency on July 22, 2025, for the supply of INLYTA 5 mg tablets in quantities of 60 units. The contract, which carries a firm fixed-price structure with an ultimate completion date of August 12, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for 60 tablets of INLYTA 5 mg, a targeted cancer therapy medication. This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with completion required by August 21, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical...
- This delivery order, valued at $23,791.44 with an ultimate completion date of September 12, 2025, awards AmerisourceBergen Drug Corp the supply of INLYTA 5 mg tablets (60-count units) under a firm fixed-price arrangement. The award was made competitively with no set-aside designation by the Defense Logistics Agency (DLA), which procures medical supplies and pharmaceuticals for the Department of Defense and military healthcare systems. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Inlyta 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This non-set-aside contract, awarded on July 21, 2025, utilizes firm fixed pricing and is scheduled for completion by August 11, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of INLYTA 5 MG TABLET 60S. The contract has a ceiling value of $11,039.62 and an ultimate completion date of October 2, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering a wide range...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3MADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of INLYTA 5 mg tablets in a quantity of 60 units, with a ceiling value of $11,895.72. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for completion by September 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. INLYTA (axitinib) is a targeted cancer therapy medication used primarily in the treatment of advanced renal cell carcinoma, reflecting the Defense Logistics Agency's procurement of specialized pharmaceutical products for military and veteran healthcare systems. This delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains extensive experience fulfilling DLA requirements across a broad spectrum of therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. The parent IDC serves military healthcare programs globally through the Defense Health Agency and other government healthcare systems, enabling flexible procurement of pharmaceutical commodities to support military medical operations and readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 9/9/25 |